{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BRAF&page=2", "query": { "condition": "BRAF", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BRAF&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T16:05:43.545Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06270082", "title": "Study of IK-595 in RAS- or RAF-altered Advanced Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "Pancreatic Cancer", "Malignant Melanoma", "Ras (Kras or Nras) Gene Mutation", "BRAF Gene Mutation", "CRAF Gene Mutation", "Non-Small Cell Lung Carcinoma", "Thyroid Carcinoma", "Gliomas, Malignant" ], "interventions": [ { "name": "IK-595", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ikena Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2023-12-18", "completion_date": "2025-09-08", "has_results": false, "last_update_posted_date": "2025-09-19", "last_synced_at": "2026-06-25T16:05:43.545Z", "location_count": 15, "location_summary": "Duarte, California • Orange, California • Denver, Colorado + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06270082" }, { "nct_id": "NCT01231568", "title": "An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Regimen A", "type": "DRUG" }, { "name": "Regimen B", "type": "DRUG" }, { "name": "Regimen C", "type": "DRUG" }, { "name": "Regimen D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2010-10-21", "completion_date": "2011-05-13", "has_results": false, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-06-25T16:05:43.545Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Detroit, Michigan • Nashville, Tennessee + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231568" }, { "nct_id": "NCT04534283", "title": "A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Cancer Metastatic", "BRAF V600E", "MEK1 Gene Mutation", "MEK2 Gene Mutation", "ERK Mutation", "RAF1 Gene Mutation" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "LY3214996", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anita Turk", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-10-05", "completion_date": "2023-08-07", "has_results": true, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-06-25T16:05:43.545Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04534283" }, { "nct_id": "NCT05388877", "title": "E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Neoplasm in the Central Nervous System", "Metastatic Melanoma" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "MEK-1/MEKK-1 Inhibitor E6201", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2022-10-20", "completion_date": "2025-06-02", "has_results": false, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-06-25T16:05:43.545Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05388877" }, { "nct_id": "NCT04117945", "title": "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRAF V600E Negative", "KRAS Gene Mutation Negative", "Locally Advanced Unresectable Colorectal Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "NRAS Gene Mutation Negative", "Stage III Colorectal Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2020-03-03", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-06-25T16:05:43.545Z", "location_count": 15, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04117945" }, { "nct_id": "NCT05806268", "title": "Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "BRAF v600 Mutated Metastatic Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 214, "start_date": "2021-07-30", "completion_date": "2022-03-28", "has_results": false, "last_update_posted_date": "2023-04-10", "last_synced_at": "2026-06-25T16:05:43.545Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05806268" }, { "nct_id": "NCT03973918", "title": "Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Glioma", "BRAF V600E", "BRAF V600K", "Anaplastic Astrocytoma", "Anaplastic Pleomorphic Xanthoastrocytoma", "Gliosarcoma", "Glioblastoma" ], "interventions": [ { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Research Bloods", "type": "BIOLOGICAL" }, { "name": "Tumor Tissue", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-07-29", "completion_date": "2023-10-01", "has_results": true, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-06-25T16:05:43.545Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Winston-Salem, North Carolina", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03973918" }, { "nct_id": "NCT05355701", "title": "A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-Small-Cell Lung Cancer", "Thyroid Cancer", "Glioma", "Advanced Colorectal Cancer (Part 1)" ], "interventions": [ { "name": "PF-07799933", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "midazolam", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 267, "start_date": "2022-07-05", "completion_date": "2029-10-25", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-25T16:05:43.545Z", "location_count": 31, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05355701" }, { "nct_id": "NCT03273153", "title": "A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced BRAFV600 Wild-type Melanoma" ], "interventions": [ { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 446, "start_date": "2017-12-11", "completion_date": "2021-02-19", "has_results": true, "last_update_posted_date": "2022-09-21", "last_synced_at": "2026-06-25T16:05:43.545Z", "location_count": 23, "location_summary": "Tucson, Arizona • Duarte, California • Los Angeles, California + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03273153" }, { "nct_id": "NCT02164916", "title": "S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "vemurafenib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2014-11", "completion_date": "2020-11-19", "has_results": true, "last_update_posted_date": "2020-12-30", "last_synced_at": "2026-06-25T16:05:43.545Z", "location_count": 763, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 489 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02164916" } ] }